Cargando…
Pioneering BRCA1/2 Point-Of-Care Testing for Integration of Germline and Tumor Genetics in Breast Cancer Risk Management: A Vision for the Future of Translational Pharmacogenomics
Research performed in South African (SA) breast, ovarian and prostate cancer patients resulted in the development of a rapid BRCA point-of-care (POC) assay designed as a time- and cost-effective alternative to laboratory-based technologies currently used for first-tier germline DNA testing. In this...
Autores principales: | Mampunye, Lwando, van der Merwe, Nerina C., Grant, Kathleen A., Peeters, Armand V., Torrorey-Sawe, Rispah, French, David J., Moremi, Kelebogile E., Kidd, Martin, van Eeden, Petrus C., Pienaar, Fredrieka M., Kotze, Maritha J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513538/ https://www.ncbi.nlm.nih.gov/pubmed/34660253 http://dx.doi.org/10.3389/fonc.2021.619817 |
Ejemplares similares
-
Pioneering Informed Consent for Return of Research Results to Breast Cancer Patients Facing Barriers to Implementation of Genomic Medicine: The Kenyan BRCA1/2 Testing Experience Using Whole Exome Sequencing
por: Torrorey-Sawe, Rispah, et al.
Publicado: (2020) -
Exome Sequencing in a Family with Luminal-Type Breast Cancer Underpinned by Variation in the Methylation Pathway
por: van der Merwe, Nicole, et al.
Publicado: (2017) -
Identification of an iron-responsive subtype in two children diagnosed with relapsing-remitting multiple sclerosis using whole exome sequencing
por: van Rensburg, Susan J., et al.
Publicado: (2019) -
Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study
por: Oosthuizen, Jaco, et al.
Publicado: (2021) -
Mutational spectrum of DNA damage and mismatch repair genes in prostate cancer
por: Bugoye, Fidelis Charles, et al.
Publicado: (2023)